{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:31:50Z","timestamp":1795095110249,"version":"4.10.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T00:00:00Z","timestamp":1665878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T00:00:00Z","timestamp":1665878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP 136938"],"award-info":[{"award-number":["MOP 136938"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Additional funders were the University of Toronto Faculty of Medicine, Banting and Best Diabetes Centre and Heart & Stroke\/Richard Lewar Centre of Excellence in Cardiovascular Research."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Combining a glucagon-like peptide-1 receptor agonist (GLP1-RA) with basal insulin is an emerging option when initiating injectable therapy in longstanding type 2 diabetes (T2DM). Recognizing that short-term insulin therapy can improve beta-cell function and induce glycemic remission in early T2DM, we hypothesized that adding the short-acting GLP1-RA exenatide to basal insulin in early T2DM may enhance the achievability of these outcomes. In this completed, 20-week, open-label, parallel-arm trial at an academic hospital, 103 individuals aged 30\u201380 years with &lt;7 years duration of T2DM were randomized (by computer-generated sequence) to 8-weeks treatment with (i) insulin glargine (Glar; <jats:italic>n<\/jats:italic>\u2009=\u200933), (ii) glargine\u2009+\u2009thrice-daily lispro (Glar\/Lispro; <jats:italic>n<\/jats:italic>\u2009=\u200935), or (iii) glargine\u2009+\u2009twice-daily exenatide (Glar\/Exenatide; <jats:italic>n<\/jats:italic>\u2009=\u200935), followed by 12-weeks washout. The analyzed population of 102 participants (median 3.5 years of T2DM, A1c 6.6% \u00b10.7%) consisted of 33 on Glar, 35 on Glar\/Lispro and 34 on Glar\/Exenatide. Oral glucose tolerance tests at baseline, 4-weeks, 8-weeks and 20-weeks enabled assessment of beta-cell function (Insulin Secretion-Sensitivity Index-2 (ISSI-2)) and glycemic control. Mean ISSI-2 over the 8-week intervention (primary outcome) did not differ across the groups (Glar\/Exenatide 237\u2009\u00b1\u200911; Glar\/Lispro 208\u2009\u00b1\u200911; Glar 223\u2009\u00b1\u200911; <jats:italic>p<\/jats:italic>\u2009=\u20090.19). Baseline-adjusted A1c at 8-weeks (secondary outcome) was lowest in Glar\/Exenatide followed by Glar\/Lispro and Glar (mean 5.9% vs 6.0% vs 6.2%; <jats:italic>p<\/jats:italic>\u2009=\u20090.0007). After 12-weeks washout, however, neither baseline-adjusted A1c nor baseline-adjusted ISSI-2 (secondary outcomes) differed between the groups, nor did (additional outcome) rates of remission (Glar\/Exenatide 26.7%, Glar\/Lispro 43.8%, Glar 32.1%; <jats:italic>p<\/jats:italic>\u2009=\u20090.35). There were no severe hypoglycemia episodes. In conclusion, adding exenatide to basal insulin in early T2DM does not further enhance underlying beta-cell function or the capacity to achieve diabetes remission, despite yielding on-treatment glycemic benefit.<\/jats:p>","DOI":"10.1038\/s41467-022-33867-9","type":"journal-article","created":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T08:02:17Z","timestamp":1665907337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-027X","authenticated-orcid":false,"given":"Ravi","family":"Retnakaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline K.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Zinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,16]]},"reference":[{"key":"33867_CR1","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41, 2669\u20132701 (2018).","journal-title":"Diabetes Care"},{"key":"33867_CR2","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck, M. A., Quast, D. R., Wefers, J. & Meier, J. J. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol. Metab. 46, 101102 (2021).","journal-title":"Mol. Metab."},{"key":"33867_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","volume":"154","author":"JB Buse","year":"2011","unstructured":"Buse, J. B. et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med. 154, 103\u2013112 (2011).","journal-title":"Ann. Intern. Med."},{"key":"33867_CR4","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.2337\/dc14-0876","volume":"37","author":"M Diamant","year":"2014","unstructured":"Diamant, M. et al. 4B Study Group. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 37, 2763\u20132773 (2014).","journal-title":"Diabetes Care"},{"key":"33867_CR5","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","volume":"384","author":"C Eng","year":"2014","unstructured":"Eng, C., Kramer, C. K., Zinman, B. & Retnakaran, R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 384, 2228\u20132234 (2014).","journal-title":"Lancet"},{"key":"33867_CR6","doi-asserted-by":"publisher","first-page":"614","DOI":"10.2337\/dc16-1957","volume":"40","author":"MI Maiorino","year":"2017","unstructured":"Maiorino, M. I. et al. Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care 40, 614\u2013624 (2017).","journal-title":"Diabetes Care"},{"key":"33867_CR7","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.2337\/dc20-0498","volume":"43","author":"JA Huthmacher","year":"2020","unstructured":"Huthmacher, J. A., Meier, J. J. & Nauck, M. A. Efficacy and safety of short- and long-acting GLP-1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis. Diabetes Care 43, 2303\u20132312 (2020).","journal-title":"Diabetes Care"},{"key":"33867_CR8","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/dom.12977","volume":"19","author":"DR Owens","year":"2017","unstructured":"Owens, D. R., Monnier, L. & Barnett, A. H. Future challenges and therapeutic opportunities in type 2 diabetes: changing the paradigm of current therapy. Diabetes Obes. Metab. 19, 1339\u20131352 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"33867_CR9","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","volume":"371","author":"J Weng","year":"2008","unstructured":"Weng, J. et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicenter randomised parallel-group trial. Lancet 371, 1753\u20131760 (2008).","journal-title":"Lancet"},{"key":"33867_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S2213-8587(13)70006-8","volume":"1","author":"CK Kramer","year":"2013","unstructured":"Kramer, C. K., Zinman, B. & Retnakaran, R. Short-term intensive insulin therapy in type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 1, 28\u201334 (2013).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"33867_CR11","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1210\/jc.2018-01468","volume":"104","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. Predictors of long-term glycemic remission after 2-week intensive insulin treatment in newly diagnosed type 2 diabetes. J. Clin. Endocrinol. Metab. 104, 2153\u20132162 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"33867_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/dia.2011.0123","volume":"14","author":"L Zeng","year":"2012","unstructured":"Zeng, L. et al. Noninferiority effects on glycemic control and beta-cell function improvement in newly-diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment. Diabetes Technol. Ther. 14, 35\u201342 (2012).","journal-title":"Diabetes Technol. Ther."},{"key":"33867_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"ORIGIN Trial Investigators.","year":"2012","unstructured":"ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 367, 319\u2013328 (2012).","journal-title":"N. Engl. J. Med."},{"key":"33867_CR14","doi-asserted-by":"publisher","first-page":"108817","DOI":"10.1016\/j.diabres.2021.108817","volume":"175","author":"MC Riddle","year":"2021","unstructured":"Riddle, M. C. The current schemes of insulin therapy: pro and contra. Diabetes Res Clin. Pract. 175, 108817 (2021).","journal-title":"Diabetes Res Clin. Pract."},{"key":"33867_CR15","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/dom.14421","volume":"23","author":"R Retnakaran","year":"2021","unstructured":"Retnakaran, R. et al. Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (RESET-IT Main): A 2-year randomized controlled trial. Diabetes Obes. Metab. 23, 1926\u20131935 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"33867_CR16","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier, J. J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 728\u2013742 (2012).","journal-title":"Nat. Rev. Endocrinol."},{"key":"33867_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.regpep.2008.07.003","volume":"151","author":"H Linnebjerg","year":"2008","unstructured":"Linnebjerg, H. et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul. Pept. 151, 123\u2013129 (2008).","journal-title":"Regul. Pept."},{"key":"33867_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.regpep.2013.04.001","volume":"185","author":"M Lorenz","year":"2013","unstructured":"Lorenz, M. et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes-relationship to postprandial glycemia. Regul. Pept. 185, 1\u20138 (2013).","journal-title":"Regul. Pept."},{"key":"33867_CR19","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1111\/dom.12968","volume":"19","author":"JJ Meier","year":"2017","unstructured":"Meier, J. J. et al. Impact of insulin glargine and lixisenatide on beta-cell function in patients with type 2 diabetes mellitus: a randomized open-label study. Diabetes Obes. Metab. 19, 1625\u20131629 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"33867_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/cen.12199","volume":"80","author":"A Gastaldelli","year":"2014","unstructured":"Gastaldelli, A., Brodows, R. G. & D\u2019Alessio, D. The effect of chronic twice daily exenatide treatment on \u03b2-cell function in new onset type 2 diabetes. Clin. Endocrinol. 80, 545\u2013553 (2014).","journal-title":"Clin. Endocrinol."},{"key":"33867_CR21","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.2337\/dc14-0893","volume":"37","author":"R Retnakaran","year":"2014","unstructured":"Retnakaran, R., Kramer, C. K., Choi, H., Swaminathan, B. & Zinman, B. Liraglutide and the preservation of pancreatic \u03b2-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 37, 3270\u20133278 (2014).","journal-title":"Diabetes Care"},{"key":"33867_CR22","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.2337\/dc19-0556","volume":"42","author":"RISE Consortium.","year":"2019","unstructured":"RISE Consortium. Lack of durable improvements in beta-cell function following withdrawal of pharmacological interventions in adults with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care 42, 1742\u20131751 (2019).","journal-title":"Diabetes Care"},{"key":"33867_CR23","doi-asserted-by":"publisher","first-page":"762","DOI":"10.2337\/dc08-1797","volume":"32","author":"MC Bunck","year":"2009","unstructured":"Bunck, M. C. et al. One year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32, 762\u2013768 (2009).","journal-title":"Diabetes Care"},{"key":"33867_CR24","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.2337\/dc11-0291","volume":"34","author":"MC Bunck","year":"2011","unstructured":"Bunck, M. C. et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34, 2041\u20132047 (2011).","journal-title":"Diabetes Care"},{"key":"33867_CR25","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2337\/dc15-2782","volume":"39","author":"FLAT-SUGAR Trial Investigators.","year":"2016","unstructured":"FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care 39, 973\u2013981 (2016).","journal-title":"Diabetes Care"},{"key":"33867_CR26","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2337\/db08-1607","volume":"58","author":"A Stanc\u00e1kov\u00e1","year":"2009","unstructured":"Stanc\u00e1kov\u00e1, A. et al. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 58, 1212\u20131221 (2009).","journal-title":"Diabetes"},{"key":"33867_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(10)60746-5","volume":"376","author":"B Zinman","year":"2010","unstructured":"Zinman, B. et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomized controlled study. Lancet 376, 103\u2013111 (2010).","journal-title":"Lancet"},{"key":"33867_CR28","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.2337\/dc13-0520","volume":"36","author":"RA Defronzo","year":"2013","unstructured":"Defronzo, R. A. et al. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care 36, 3607\u20133612 (2013).","journal-title":"Diabetes Care"},{"key":"33867_CR29","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","volume":"22","author":"M Matsuda","year":"1999","unstructured":"Matsuda, M. & DeFronzo, R. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462\u20131470 (1999).","journal-title":"Diabetes Care"},{"key":"33867_CR30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412\u2013419 (1985).","journal-title":"Diabetologia"},{"key":"33867_CR31","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/oby.2008.307","volume":"16","author":"R Retnakaran","year":"2008","unstructured":"Retnakaran, R. et al. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity 16, 1901\u20131907 (2008).","journal-title":"Obesity"},{"key":"33867_CR32","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/j.1464-5491.2009.02841.x","volume":"26","author":"R Retnakaran","year":"2009","unstructured":"Retnakaran, R., Qi, Y., Goran, M. I. & Hamilton, J. K. Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet. Med. 26, 1198\u20131203 (2009).","journal-title":"Diabet. Med."},{"key":"33867_CR33","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.2337\/dci21-0034","volume":"44","author":"MC Riddle","year":"2021","unstructured":"Riddle, M. C. et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care 44, 2438\u20132444 (2021).","journal-title":"Diabetes Care"},{"key":"33867_CR34","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.2337\/dc14-1529","volume":"37","author":"CK Kramer","year":"2014","unstructured":"Kramer, C. K. et al. Each degree of glucose intolerance in pregnancy predicts distinct trajectories of beta-cell function, insulin sensitivity and glycemia in the first 3 years postpartum. Diabetes Care 37, 3262\u20133269 (2014).","journal-title":"Diabetes Care"},{"key":"33867_CR35","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/bmj.312.7027.364","volume":"312","author":"RJ Glynn","year":"1996","unstructured":"Glynn, R. J. & Buring, J. E. Ways of measuring rates of recurrent events. BMJ 312, 364\u2013367 (1996).","journal-title":"BMJ"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33867-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33867-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33867-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T08:02:29Z","timestamp":1665907349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33867-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["33867"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-33867-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,16]]},"assertion":[{"value":"9 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RR reports grants from Boehringer Ingelheim, grants and personal fees from Novo Nordisk, personal fees from Sanofi, personal fees from Eli Lilly, outside the submitted work. CKK reports research support from Boehringer Ingelheim, outside the submitted work. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6109"}}